Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL versus MINOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL versus MINOCIN.
DOXYCHEL vs MINOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
100 mg orally or intravenously every 12 hours for 24 hours, then 100 mg every 12 hours; severe infections: 200 mg initially, then 100 mg every 12 hours.
None Documented
None Documented
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
Terminal elimination half-life is 11–17 hours in patients with normal renal function; prolonged up to 18–69 hours in renal impairment.
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Primarily renal (approximately 70% unchanged) and biliary/fecal (approximately 30%, with enterohepatic recycling).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic